跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 489 条关于
“lerodalcibep-liga”
全部
489
临床试验
376
药物
18
机构
7
资讯
88
9个月前
FDA Approves Lerodalcibep-liga (LEROCHOL) as Third-Generation PCSK9 Inhibitor for Cholesterol Management
9个月前
FDA Approves Plozasiran for Familial Chylomicronemia Syndrome, Marking Breakthrough in Rare Lipid Disorder Treatment
去年
FDA Accepts Review of Lerodalcibep for LDL Cholesterol Reduction
9个月前
Everest Medicines Secures Exclusive Greater China Rights to Novel PCSK9 Inhibitor Lerodalcibep
去年
LIB Therapeutics' Lerodalcibep BLA Accepted by FDA for LDL-C Reduction
去年
Lerodalcibep Shows Promise in Lowering LDL-C in HoFH Patients
去年
FDA Approves IND Application for NextCure's B7-H4-Targeting ADC, LNCB74, for Solid Tumors
2年前
Parkinson's Drug DNL-151 Phase III Trial Terminated; Lerodalcibep Shows Promise in Hypercholesterolemia
去年
NIAB Scientists Develop Next-Generation Leptospirosis Vaccine Strategy
2个月前
Everest Medicines' LEROCHOL BLA Accepted by China NMPA for Hypercholesterolemia
第 1 页,共 9 页
上一页
下一页